Literature DB >> 20427775

APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions.

Luigia Pace1, Sara Vitale, Beatrice Dettori, Cecilia Palombi, Valentina La Sorsa, Filippo Belardelli, Enrico Proietti, Gino Doria.   

Abstract

Type I IFNs are central to a vast array of immunological functions. Their early induction in innate immune responses provides one of the most important priming mechanisms for the subsequent establishment of adaptive immunity. The outcome is either promotion or inhibition of these responses, but the conditions under which one or the other prevails remain to be defined. The main objective of the current study was to determine the involvement of IFN-alpha on murine CD4(+)CD25(-) Th cell activation, as well as to define the role played by this cytokine on CD4(+)CD25(+) regulatory T (Treg) cell proliferation and function. Although IFN-alpha promotes CD4(+)CD25(-) Th cells coincubated with APCs to produce large amounts of IL-2, the ability of these cells to respond to IL-2 proliferative effects is prevented. Moreover, in medium supplemented with IFN-alpha, IL-2-induced CD4(+)CD25(+) Treg cell proliferation is inhibited. Notably, IFN-alpha also leads to a decrease of the CD4(+)CD25(+) Treg cell suppressive activity. Altogether, these findings indicate that through a direct effect on APC activation and by affecting CD4(+)CD25(+) Treg cell-mediated suppression, IFN-alpha sustains and drives CD4(+)CD25(-) Th cell activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427775     DOI: 10.4049/jimmunol.0900526

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 2.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

3.  Induction of immunogenic cell death by targeting RIG-I-like helicases in pancreatic cancer.

Authors:  Max Schnurr; Peter Duewell
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 4.  Type I interferon in the pathogenesis of lupus.

Authors:  Mary K Crow
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

5.  Type I IFN gene delivery suppresses regulatory T cells within tumors.

Authors:  H Hashimoto; R Ueda; K Narumi; Y Heike; T Yoshida; K Aoki
Journal:  Cancer Gene Ther       Date:  2014-11-28       Impact factor: 5.987

Review 6.  Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation.

Authors:  Kate S Smigiel; Shivani Srivastava; J Michael Stolley; Daniel J Campbell
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

7.  Beta interferon controls West Nile virus infection and pathogenesis in mice.

Authors:  Helen M Lazear; Amelia K Pinto; Matthew R Vogt; Michael Gale; Michael S Diamond
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

8.  IFNαR signaling in effector but not regulatory T cells is required for immune dysregulation during type I IFN-dependent inflammatory disease.

Authors:  Shivani Srivastava; Lisa K Koch; Daniel J Campbell
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

9.  RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.

Authors:  P Duewell; A Steger; H Lohr; H Bourhis; H Hoelz; S V Kirchleitner; M R Stieg; S Grassmann; S Kobold; J T Siveke; S Endres; M Schnurr
Journal:  Cell Death Differ       Date:  2014-07-11       Impact factor: 15.828

10.  Harnessing Apoptotic Cells for Transplantation Tolerance: Current Status and Future Perspectives.

Authors:  Anil Dangi; Xunrong Luo
Journal:  Curr Transplant Rep       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.